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Introduction: Despite a current lack of U.S. Food and Drug Administration approval for the indication, thoracic endo-
vascular aortic repair (TEVAR) has replaced open surgical management for acute complicated type B aortic dissection due
to promising short- and midterm data. However, long-term results, with a view toward durability and need for secondary
procedures, are limited. As such, the objective of the present study is to report long-term outcomes of TEVAR for acute
(#2 weeks from symptom onset) complicated type B dissection.
Methods: Between July 2005 and September 2012, 50 consecutive patients underwent TEVAR for management of acute
complicated type B dissection at a single referral institution. Patient records were retrospectively reviewed from
a prospectively maintained clinical database.
Results: Indications for intervention included rupture in 10 (20%), malperfusion in 24 (48%), and/or refractory pain/
impending rupture in 17 (34%). One patient (2%) had both rupture and malperfusion indications. Ten (20%) patients
required one or more adjunctive procedures, in addition to TEVAR, to treat malperfusion syndromes. In-hospital and 30-
day rates of death were both 0%; 30-day/in-hospital rates of stroke, permanent paraplegia/paraparesis, and new-onset
dialysis were 2% (n [ 1), 2% (n [ 1), and 4% (n [ 2), respectively. Median follow-up was 33.8 months [interquartile
range, 12.3-56.6 months]. Overall survival at 5 and 7 years was 84%, with no deaths attributable to aortic pathology.
Thirteen (26%) patients required a total of 17 reinterventions over the study period for type I endoleak (n [ 5),
metachronous aortic pathology (n [ 5), persistent false lumen pressurization via distal fenestrations (n [ 4), type II
endoleak (n [ 2), or retrograde acute type A aortic dissection (n [ 1). Median time to ﬁrst reintervention was
4.5 months (range, 0 days-40.3 months). Of the 17 total reinterventions, six (35%) were performed using open tech-
niques and 11 (65%) with endovascular or hybrid methods; there was no difference in survival between patients who did
or did not require reintervention.
Conclusions: This study conﬁrms the excellent short-term outcomes of TEVAR for acute complicated type B dissection
and demonstrates the results to be durable and sustained over long-term follow-up. Although aortic reinterventions were
required in one-quarter of patients, no aortic-related deaths were observed. These data support the use of TEVAR for
acute complicated type B aortic dissection but also highlight the importance of life-long aortic surveillance by an expe-
rienced aortic referral center in order to identify and treat complications of the underlying disease process and treatment,
as well as new aortic pathologies, as they arise. (J Vasc Surg 2014;59:96-106.)Acute type B aortic dissection (identiﬁed within 2 weeks
of symptom onset) accounts for 25% to 40% of all aortic
dissections.1 The majority of patients with uncomplicated
disease can be treated with intensive medical management.2
However, up to 20% of patients develop complications such
as rupture, branch-vessel malperfusion, or refractory pain or
hypertension, necessitating urgent surgical or interventional
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://dx.doi.org/10.1016/j.jvs.2013.07.001Surgical repair has been the standard of care for the
treatment of acute complicated type B aortic dissection,
and treatment options have included direct aortic rep-
lacement, extra-anatomic revascularization (eg, axillary-
femoral bypass) for lower extremity ischemia, and surgical
or percutaneous fenestration for visceral malperfusion.7,8
Despite advances in surgical technique and postoperative
management, conventional open surgery for acute compli-
cated type B dissection is associated with an operative
mortality ranging from 15% to 30% and considerable
morbidity including spinal cord ischemia, cerebrovascular
accident, and renal failure.9,10 Additionally, for patients pre-
senting with both malperfusion and rupture, in-hospital
mortality increases to as high as 63%.10
As a result of the signiﬁcant morbidity and mortality
associated with conventional treatment options, thoracic
endovascular aortic repair (TEVAR) has largely replaced
open surgery as the preferred treatment for acute compli-
cated type B aortic dissection, despite a lack of current
U.S. Food and Drug Administration approval for this indi-
cation.11-18 The goals of therapy in the acute phase involve
restoration of true lumen ﬂow with closure of the primary
tear, abrogation of frank or impending aortic rupture,
and relief of dynamic malperfusion. Delayed beneﬁts are
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mitigating the risk of subsequent aortic rupture from aneu-
rysmal dilatation.19 Despite the accelerated use of TEVAR
for the treatment of acute complicated type B dissection,
long-term results with a view toward durability and need
for secondary procedures are limited. Therefore, the
purpose of this study was to examine our institutional expe-
rience with TEVAR for the treatment of acute complicated
type B dissection and detail 30-day and long-term outcome
data.
METHODS
Patient population and data collection. This study
was approved by the Institutional Review Board of Duke
University Medical Center, and the need for individual
patient consent was waived. The Duke Thoracic Aortic
Surgery Database is a prospectively maintained electronic
clinical registry of all patients who have undergone thoracic
aortic surgery at Duke UniversityMedical Center (Durham,
NC) since 2005.20,21 A query of the database identiﬁed 50
consecutive TEVAR operations performed between July
2005 and September 2012 for repair of acute complicated
dissection of the descending thoracic aorta, and these form
the basis of this report. Indications for repair included one or
more of the following clinical or anatomical characteristics:
free or contained rupture (n ¼ 10; 20%); clinical or radio-
graphic evidence of malperfusion (n ¼ 24; 48%); and
refractory pain/impending rupture (n ¼ 17; 34%). Refrac-
tory pain was deﬁned as ongoing symptoms of back and/or
chest pain requiring narcotic medications in the presence of
excellent blood pressure control. One patient (2%) had both
rupture and malperfusion indications. No patient required
intervention for refractory hypertension in the absence of
concurrent renal malperfusion. No patient underwent
intervention for uncomplicated acute type B dissection as
per our previously published institutional practice of initial
medical management for these patients in the absence of
data to support a more aggressive approach.5 Further, no
patient underwent open repair for acute complicated type B
dissection during this time interval as TEVAR has replaced
open repair as the procedure of choice for this condition
both in our institution and in recent consensus management
guidelines.1,8 Data were collected through the last follow-up
by the study termination date of December 2012.
All procedural outcomes and complications were pros-
pectively recorded, and follow-up was performed at the
Duke University Center for Aortic Surgery. Primary tech-
nical success was deﬁned according to Society of Vascular
Surgery reporting standards.22 Patient follow-up protocols
were similar to prior clinical trials23,24 and included clinical
examination and computed tomography angiography
(CTA) at 1, 6, and 12 months postoperatively and annually
thereafter. Additional 3-month imaging was performed if
an endoleak was identiﬁed at the 1-month follow-up and
nonoperative management pursued. Endoleak was deﬁned
as in the two now completed industry-sponsored clinical
trials of TEVAR for acute complicated type B dissec-
tion.25,26 Speciﬁcally, persistent false lumen perfusionoriginating from fenestrations downstream from the endog-
raft(s) was not considered a type I endoleak, as the ﬂow did
not originate from either the proximal or distal anchoring
site of the device. Perfusion of the false lumen originating
from retrograde ﬂow from either the left subclavian artery
(LSCA) or intercostal or bronchial arteries along the length
of stent-grafted aorta was classiﬁed as a type II endoleak.
Operative techniques. A TeraRecon Aquarius iNtui-
tion 3D workstation (TeraRecon Inc, San Mateo, Calif)
was used for preoperative case planning to perform center-
line measurements of aortic and ﬂow lumen diameters and
evaluate landing zones and access vessels. In all cases, the
endovascular stent graft was sized to the nondissected
proximal aorta using the mean luminal diameter as deter-
mined from centerline analysis. Endografts used were the
Gore TAG (W. L. Gore and Associates, Flagstaff, Ariz) in
29, Gore C-TAG in 8, the Zenith TX2 (Cook Medical
Inc, Bloomington, Ind) in 4, the Medtronic Talent (Med-
tronic Endovascular, Santa Rosa, Calif) in 4, and the Med-
tronic Valiant with Captiva in 5.
All procedures were performed in the operating room
under general anesthesia; adjunctive transesophageal echo-
cardiography (TEE)was used in all cases. Intravascular ultra-
sound (IVUS; Volcano Corporation, San Diego, Calif) was
also routinely used to verify true lumen access, identify the
primary entry tear and areas of distal fenestration, evaluate
proximal and distal landing zones, and conﬁrm true lumen
re-expansion and resolution of dynamic malperfusion after
intervention as previously described.27 Online monitoring
of spinal cord function with somatosensory and motor
evoked potentials was used intraoperatively in urgent cases
and when available for emergent cases, for a total of 37
(74%) cases monitored, as previously described.28 Cerebro-
spinal ﬂuid (CSF) drainagewas used selectively in six patients
(12%) for previously cited indications, generally including
patients who had undergone prior thoracic or abdominal
aortic operations and in whom long-segment aortic
coverage was planned.29,30 Two additional patients received
a preoperative lumbar drain for paraparesis secondary to
dissection-induced spinal cord malperfusion.
An iliac or abdominal aortic conduit was required for
vascular access in four patients (8%). The LSCA was partially
or fully covered in 36 (72%) patients, of whom ﬁve (14%)
underwent adjunctive left carotid-subclavian bypass at the
time of TEVAR for previously described indications,
including a patent pedicled left internal mammary artery
graft, left arm dialysis access, origin of the left vertebral artery
from the aortic arch, a dominant left vertebral artery with
diminutive right vertebral artery, patients considered high
risk for paraplegia due to planned aortic pavement from
the LSCA to the celiac axis, prior abdominal aortic aneurysm
or other thoracic or thoracoabdominal aortic repair, or prior
hypogastric artery ligation or embolization.31
Operative intervention centered on a malperfusion- and
rupture-speciﬁc approach to repair. For patients with branch
vessel compromise due to occlusion of the true lumen by
the pressurized false lumen, endovascular treatment aimed
to address this dynamic malperfusion by restoring antegrade
Fig 1. Axial computed tomography angiography (CTA) image of
a patient with an acute type B aortic dissection and contained
aortic rupture. As can be seen from the image, the large bloody left
pleural effusion and periaortic hematoma frequently obscure the
original site of leak and complete thoracic endograft coverage is
required.
Table I. Demographics and comorbidities
Variable
Acute type B
aortic dissection
repair (n ¼ 50)
Age, years 59.0 (53.3-70.0)
Male gender 36 (72)
White race 26 (52)
Body mass index, kg/m2 28.4 (25.2-31.0)
Marfan syndrome 4 (8)
Hyperlipidemia 23 (46)
Prior aortic surgery 11 (22)
Diabetes mellitus 6 (12)
Hypertension 46 (92)
Tobacco use 28 (56)
Chronic obstructive pulmonary disease 7 (14)
Renal insufﬁciency (baseline Cr > 1.5 mg/dL) 17 (34)
History of stroke/transient ischemic attack 3 (6)
Coronary artery disease 9 (18)
Cr, Creatinine.
Data shown as median (interquartile range) or number (%).
Table II. Clinical and radiographic characteristics on
admission
Variable
Acute type B
aortic dissection
repair (n ¼ 50)
Systolic blood pressure on admission, mm Hg 156 6 37
Diastolic blood pressure on admission, mm Hg 77 6 22
Hypotension/shock on admission 2 (4)
Clinical or radiographic malperfusion on
admission
24 (48)
Visceral malperfusion 11 (22)
Renal malperfusion 10 (20)
Iliofemoral malperfusion 13 (26)
Spinal malperfusion 2 (4)
Pain at presentation 49 (98)
Back pain 35 (70)
Anterior chest pain 26 (52)
Refractory pain/impending rupture 17 (34)
Intramural hematoma 7 (14)
Rupture 10 (20)
Contained 9 (90)
Free 1 (10)
Maximum diameter of descending aorta, cm 4.8 6 1.0
Data shown as mean 6 standard deviation or number (%).
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the primary tear and all distal thoracic fenestrations. Adjunc-
tive distal bare metal stenting (PALMAZ balloon ex-
pandable stent; Cordis Corporation, Miami Lakes, Fla;
WALLSTENT self-expanding stent; Boston Scientiﬁc,
Natick, Mass) of the visceral segment and/or iliac vessels
was performed based on angiographic and IVUS assessment
after deployment of the thoracic endograft(s); bare metal
or covered stent placement in the infrarenal aorta was like-
wise utilized as necessary for persistent malperfusion of
the abdominal aorta after proximal thoracic endografting.
In the case of long segment unilateral iliac occlusion,
femoral-femoral bypass was used to restore adequate perfu-
sion in conjunction with aortouni-iliac infrarenal device
placement. In the case of staticmalperfusion caused by prop-
agation of the dissection into branch vessel ostia with distal
vessel occlusion, restoration of true lumen ﬂow by coverage
of the primary tear alone will generally not relieve the mal-
perfusion syndrome, and, therefore, adjunctive branch
vessel stenting was used to restore branch vessel patency.
Patients with contained or frank rupture required sealing
off the primary tear as well as the site of leak and frequently
necessitated paving the entire thoracic aorta when the site of
leak was unclear (Fig 1). Postdeployment balloon molding
of the endografts was not routinely performed but rather
was used selectively for cases of inadequate device seal.
IVUS and TEE were used to examine the ascending aorta
at the conclusion of all cases to assess for retrograde
ascending aortic dissection.32,33
Statistical analysis. The Social Security Death Index
(http://ssdi.rootsweb.com/) was queried to conﬁrm all
deaths and survey patients lost to follow-up. Survival and
freedom from reintervention analyses were performed
using the Kaplan-Meier method. Calculations were per-
formed using SAS 9.3 (SAS Institute Inc, Cary, NC).RESULTS
Patient demographics and operative characteristics.
Patient demographics are presented in Table I. Though the
presence of a connective tissue disorder such as the Marfan
syndrome has been considered an absolute contraindication
to TEVAR in the chronic setting, we did not consider this
a contraindication in the acute setting, where endograft
therapy has been described as a bridging technique to
subsequent deﬁnitive open repair.34 As such, in this series,
four patients (8%) with the Marfan syndrome were treated
for acute complicated type B dissection with TEVAR. Prior
aortic operations in 11 patients (22%) included abdominal
aneurysm repair in four (three open, one endovascular),
open thoracic aortic aneurysm repair in four (three
Table III. Operative characteristics
Variable
Acute type B aortic
dissection repair
(n ¼ 50)
Proximal landing zone (classiﬁcation by Ishimaru et al41)
1 2 (4)
2 34 (68)
3 4 (8)
4 10 (20)
Length of aortic coverage
Above T6 18 (36)
Below T6 to celiac axis 0 (0)
Above T6 to celiac axis 24 (48)
Above T6 to below celiac axis 8 (16)
Below T6 to below celiac axis 0 (0)
Number of thoracic endografts implanted 1 (1-4)
Thoracic endograft length, cm 20 (15-20)
Data shown as median (range) or number (%). The image is reproduced with permission from Fillinger et al.22
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tion repair in three. Clinical and radiographic characteristics
at presentation are summarized in Table II. Back and/or
anterior chest pain were present in 49 patients (98%) on
presentation, with one patient presenting to the emergency
department with complaints of shortness of breath and
a chest computed tomography scan demonstrated acute type
B aortic dissection with radiographic renal malperfusion and
refractory hypertension. Clinical or radiographic evidence of
malperfusion was present in 24 patients (48%); no patient
underwent intervention for radiographic malperfusion
without clinical correlate. Aortic rupture was present in 10
patients (20%), of whom one had free rupture and was
hemodynamically unstable at the time of operation. Prox-
imal landing zone, extent of stent graft coverage, and
number of thoracic stent grafts implanted is summarized in
Table III. Of note, two patients required covering of the left
common carotid, necessitating right-to-left carotid-to-
carotid bypass. One patient status post prior infrarenal
abdominal aortic aneurysm repair 20 years prior required
adjunctive four-vessel visceral debranching along with
thoracic endografting for treatment of bilateral renal artery
dynamic malperfusion and associated 7-cm extent III thor-
acoabdominal aortic aneurysm (TAAA).35 The median
number of thoracic stent graft components per case was one
(range, 1-4). Ten patients required adjunctive procedures to
restore visceral or extremity perfusion despite endovascular
restoration of true lumen ﬂow (Table IV; Fig 2).
Procedural (30-day/in-hospital) and follow-up
outcomes. Procedural and late outcomes are demonstrated
in Table V. Primary technical success, deﬁned as endograftdeployment without type I or III endoleak and absence of
open surgical conversion or death within 24 hours of the
operation,22 was achieved in 49 of 50 patients (98%), with
a single patient requiring sternotomy for emergent repair of
retrograde acute type A aortic dissection detected on
completion TEE after endovascular repair. Operative death,
deﬁned as death within 30 days of the procedure or during
the same hospital admission, was 0%.
The median postoperative length of stay was 5 days
(interquartile range, 3-7 days). One patient (2%) developed
a stroke. Additionally, one patient (2%) suffered permanent
paraparesis/paraplegia. Delayed transient paraparesis devel-
oped in one patient on postoperative day 0 that resolved
with blood pressure augmentation and did not require
CSF drainage. An additional patient manifested a clinically
silent minor subarachnoid hemorrhage attributable to iatro-
genic insult (CSF drainage). Two patients (4%) developed
the need for new-onset dialysis.
Median duration of follow-up was 33.8 months (inter-
quartile range, 12.3-56.6 months). Actuarial freedom from
reintervention was 94% at 30 days, 76% at 1 year, and 69%
at 72 months after TEVAR (Fig 3). Three patients required
additional endovascular or open procedures within 30 days
of the original endovascular repair for a rate of 6%. Reasons
for early reintervention included persistent false lumen
pressurization via distal fenestrations requiring repeat
TEVAR with distal extension, partial Gore TAG stent graft
collapse with persistent type IA endoleak requiring repeat
TEVAR with proximal and distal extension endografting
and the aforementioned patient with acute retrograde
type A aortic dissection requiring emergent aortic root
Fig 2. Three-dimensional computed tomography angiography
(CTA) reconstruction demonstrating patient status postproximal
thoracic endografting, aortouni-iliac endografting, and femoral-
femoral (fem-fem) bypass for the management of complicated
acute type B dissection with long-segment left iliac occlusion.
Table V. Outcomes
Variable
Acute type B
aortic dissection
repair (n ¼ 50)
30-day/in-hospital adverse events
Stroke 1 (2)
Permanent paraplegia/paraparesis 1 (2)
Acute renal failure (Cr > 2.0 and
2  baseline)
4 (8)
New onset dialysis 2 (4)
Prolonged mechanical ventilation
(>48 hours)
4 (8)
Myocardial infarction 0 (0)
Postoperative length of stay, days 5 (3-7)
Reintervention 13 (26)
Open 5 (38)
Endovascular 8 (62)
Time to ﬁrst reintervention, months 4.5 (1.4-8.1)
Death
30-day/in-hospital death 0 (0)
Late death 8 (16)
Aorta-related deaths 0 (0)
Follow-up, months 33.8 (12.3-56.6)
Cr, Creatinine.
Data shown as median (interquartile range) or number (%).
Table IV. Adjunctive procedures required for malperfusion
Site of malperfusion Description
1. Left lower extremity and left renal Left iliac and left renal artery stenting
2. Left upper extremity and visceral Left carotid-subclavian bypass, left brachial-brachial bypass, exploratory laparoscopy
3. Visceral Superior mesenteric artery angioplasty and stenting
4. Vertebrobasilar Left carotid-subclavian bypass, right carotid-subclavian bypass in patient with aberrant
LSCA in which both subclavian arteries covered by the proximal endograft
5. Renal Mesenteric debranching (left external iliac to superior mesenteric artery/left renal artery/
hepatic artery/right renal artery bypass) in patient with bilateral renal malperfusion and
7-cm extent III TAAA
6. Renal Left renal artery angioplasty and stenting
7. Bilateral iliofemoral Deployment of right aortouni-iliac device, right-to-left femoral-femoral bypass
8. Bilateral iliofemoral Right common iliac artery bare metal stenting; left common and external iliac artery bare
metal stenting
9. Bilateral iliofemoral Right and left common iliac artery bare metal stenting
10. Bilateral iliofemoral and spinal Deployment of right aortouni-iliac device, right-to-left femoral-femoral bypass
LSCA, Left subclavian artery; TAAA, thoracoabdominal aortic aneurysm.
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Overall median time to ﬁrst reintervention was 4.5 months,
with reinterventions required in 13 patients (26%).
Including the early (30-day) reinterventions, a total of
four patients (31%) required initial reintervention for type
I endoleak, three (23%) for metachronous aortic pathology
separate from the initially treated dissection, three (23%)
for false lumen dilation developing downstream to the
initially placed endograft secondary to persistent false
lumen pressurization via distal fenestrations, two (15%)
for type II endoleak via the LSCA, and one (8%) for the
previously described retrograde type A dissection. An addi-
tional four repeat reinterventions were required in three ofthese patients for persistent type 1A endoleak and subse-
quent development of metachronous aortic pathology
(abdominal aortic aneurysm) in one, persistent false lumen
pressurization via distal fenestrations in one, and develop-
ment of new metachronous aortic pathology (distal
descending thoracic aneurysm) in one. Overall, of the 17
total reinterventions, six (35%) were performed using
open techniques and 11 (65%) with endovascular or hybrid
methods. Of note, of the four Marfan patients treated by
TEVAR, three required open reintervention in follow-up
and represent three of the six total open reinterventions.
Overall, 47 patients (94%) underwent at least one
follow-up CTA scan; of the three who did not, one was
lost to follow-up and died of complications of HIV prior
to follow-up imaging, and two patients likewise died of
SE
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Fig 3. Actuarial (Kaplan-Meier) freedom from reintervention. SE, Standard error.
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following surgery and did not return for follow-up. The inci-
dence of type I or III endoleak at any follow-up visit was 8%
(n ¼ 4). Two of these were seen on the initial postoperative
CT scan and were treated with additional endovascular
repair, with complete resolution at most recent follow-up.
An additional two were recognized in long-term follow-
up, one that was treated with additional endovascular repair
and the other seen in conjunction with a new proximal
descending thoracic aortic aneurysm that was treated with
a hybrid arch debranching procedure. Four type II endo-
leaks (8%) were noted on follow-up imaging due to inter-
costal vessels and are being followed up with decreasing
(n¼ 1) or stable (n¼ 3) aortic diameters. Of the 47 patients
who had at least one follow-up CT scan, 72% exhibited false
lumen thrombosis of at least the length of the stent graft(s),
while 28% continue to have some retrograde false lumen
ﬂow along some portion of the endograft(s) via distal down-
stream fenestrations (Table VII).
Two patients (4%) required late conversions to open
repair. One underwent successful TEVAR for an acute
type B dissection with contained rupture. Subsequent
surveillance CTA indicated persistent retrograde ﬁlling of
the distal false lumen from a re-entry tear in the visceral
segment that promoted progressive dilation of his descend-
ing thoracic aorta to a diameter of 8.5 cm during a 6-month
period.He underwent successful open repair of the descend-
ing aneurysm using cardiopulmonary bypass with deep
hypothermic circulatory arrest. The second open conversion
was in a Marfan patient who likewise underwent successful
TEVAR for an acute type B dissection with intramural
hematoma, refractory pain, and two penetrating atheroscle-
rotic ulcers in the descending thoracic aorta after previoustype A dissection repair 16 years prior. Subsequent surveil-
lance CTA indicated persistent retrograde ﬁlling of the distal
false lumen and development of a 6.8-cm extent I TAAA
associated with chronic residual dissection. The patient
underwent successful open repair of the TAAA using cardio-
pulmonary bypass and deep hypothermic circulatory arrest.
Overall actuarial survival was 84% at 84 months, with an
aorta-speciﬁc actuarial survival of 100% (Fig 4). All eight
late deaths were due to comorbid conditions, including
failure to thrive in two, sepsis in one, drug overdose in
one, complications of femoral neck fracture in one, HIV
in one, chronic renal failure in one, and metastatic prostate
cancer in one. Overall survival was equivalent between
patients who did or did not require aortic reintervention
(Fig 5).DISCUSSION
Data from the International Registry of Acute Aortic
Dissection (IRAD) indicate that complicated acute type
B dissection patients undergoing open repair for malperfu-
sion or frank or impending rupture suffer a profound phys-
iologic insult substantiated by a nearly 30% perioperative
mortality rate.10 Further, this IRAD study demonstrated
a composite neurologic morbidity (cerebrovascular acci-
dent, coma, paraplegia) rate of nearly 25%, and a renal
failure rate approaching 20%. The advent of thoracic
endografting represents an advance in the treatment of
this pathology,8 as evidenced by the clinical success rate
of 100%, along with rates of 30-day/in-hospital death,
stroke, and permanent paraplegia/paraparesis of 0%, 2%,
and 2%, respectively, in this series. Similar results have
been reported by others.11-14
Table VII. Extent of false lumen thrombosis at last
radiographic follow-up
Extent false lumen
thrombosisa
Acute type B aortic
dissection repair (n ¼ 47),b No. (%)
0 13 (27.7)
I 10 (21.3)
II 12 (25.5)
III 12 (25.5)
aClassiﬁcation of false lumen thrombosis42; 0, designates some retrograde
false lumen perfusion along stent graft(s); I, designates thrombosis along
length of stent graft(s); II, designates thrombosis of false lumen throughout
thoracic aorta; III, designates complete thrombosis of false lumen
throughout entire aorta.
bn ¼ 47 because three patients in the series did not undergo follow-up
imaging (one death, two lost to follow-up).
Table VI. Reinterventions
Patient Reason for reintervention Procedure
Time to
reintervention, months
1 Type II endoleak via the LSCA Proximal extension TEVAR, LSCA
coil embolization
5.0
2 a) Proximal type IA endoleak Proximal extension TEVAR 1.4
b) Persistent type IA endoleak Zone 0 hybrid arch debranching 1.5
c) Metachronous aortic pathology (AAA) Open AAA repair 40.3
3 a) Persistent false lumen pressurization via distal fenestrations Distal extension TEVAR 1.0
b) Persistent false lumen pressurization via distal fenestrationsOpen DTAA repair 5.8
4 Partial proximal endograft collapse and type IA endoleak Proximal extension TEVAR with LSCA
coverage
30.5
5 a) Metachronous aortic pathology (ascending aneurysm) Ascending aortic and hemi-arch replacement 10.8
b) Metachronous aortic pathology (DTAA) Distal extension TEVAR 11.1
6 Metachronous aortic pathology (ascending aneurysm) Ascending aortic and hemi-arch replacement 1.6
7 Distal type IB endoleak, proximal descending TAA above
existing stent graft
Zone 0 hybrid arch debranching with distal
extension endograft
13.6
8 Partial endograft collapse and type IA endoleak Proximal and distal extension TEVAR 0.2
9 Persistent false lumen pressurization via distal fenestrations a) Distal extension TEVAR
b) EVAR of abdominal dissection
4.5
10 Acute retrograde TAAD Aortic root reconstruction with AV
resuspension
0.0
11 Persistent false lumen pressurization via distal fenestrations
and type II endoleak via LSCA
a) Distal extension TEVAR
b) EVAR of abdominal dissection
c) Occlusion of LSCA
5.1
12 Persistent false lumen pressurization via distal fenestrations Open TAAA repair 2.3
13 Metachronous aortic pathology (DTAA) Proximal and distal extension TEVAR 8.1
AAA, Abdominal aortic aneurysm; AV, aortic valve; DTAA, descending thoracic aortic aneurysm; EVAR, endovascular abdominal aortic aneurysm repair;
LSCA, left subclavian artery; TAA, thoracic aortic aneurysm; TAAA, thoracoabdominal aortic aneurysm; TAAD, type A aortic dissection; TEVAR, thoracic
endovascular aortic repair.
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broadening the indications for TEVAR in acute type B
dissection, we believe that at the present time TEVAR
should be reserved for complicated cases. Initial (30-day)
mortality is 10% or less with medical therapy in uncompli-
cated acute type B dissection, and data from the Investiga-
tion of Stent Grafts in Patients With Type B Aortic
Dissection (INSTEAD) trial suggested no therapeutic
advantage to indiscriminate endograft placement (10%
1-year mortality) vs standard medical therapy (3% 1-year
mortality) for uncomplicated subacute (2-52 weeks) type
B dissection, although this study admittedly has many ﬂaws
including randomizing only low-risk uncomplicatedpatients, small patient numbers with short duration of
follow-up, and an unacceptably high incidence (6%) of
aorta-related deaths in the TEVAR group, which were
mainly due to periprocedural complications using an earlier
generation endograft suboptimal for this application.10,28,36
That being said, up to 40% of patients with initially uncom-
plicated type B dissection are subject to aneurysmal degen-
eration in late follow-up,37 and the role of TEVAR for the
subset of uncomplicated patients with a predilection for
this complication remains undeﬁned. For example, Marui38
reported an actuarial freedom from late aortic events of only
8% at 10 years in 141 patients with acute uncomplicated
type B dissection who initially presented with an aortic
diameter exceeding 4 cm and a patent false lumen on radio-
graphic evaluation, and the author recommended early
intervention for patients with these anatomic risk factors.
Similarly, Song39 found that for patients presenting with
uncomplicated descending dissection and an initial false
lumen diameter at the upper thoracic aorta of $22 mm,
initial false lumen diameter was the most powerful predictor
of late aneurysmal change, and early TEVAR may be
warranted in this cohort. Further study is therefore needed
to identify the subset of “high-risk” uncomplicated patients
who may beneﬁt from early endovascular repair.5
The present study demonstrates the beneﬁts of
TEVAR for acute complicated type B dissection are
tempered by the need for reintervention, which appears
higher than the 3% rate cited with conventional open
repair.40 For example, two patients developed type II
Fig 4. Actuarial (Kaplan-Meier) overall (solid line) and aorta-speciﬁc (dashed line) survival. SE, Standard error.
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experience, concomitant endovascular occlusion of the
LSCA, when it was covered by the endograft, was not
uniformly performed, but as further experience demon-
strated the LSCA to be a source of persistent retrograde
ﬂow that prevented thrombosis of the false lumen,
concomitant occlusion became routine. Additionally, three
patients (6%) early in the series required late reintervention
with additional distal endografting for downstream dila-
tion. Given this experience, we now have a low threshold
to pave down to the celiac axis in the acute setting, as
extensive endografting of the thoracic aorta has not
appeared to signiﬁcantly increase neurologic morbidity
based on the data presented. Overall, two patients (4%)
failed endovascular repair and went on to hybrid or open
repairs, including zone 0 hybrid arch debranching and
open TAAA repair. Moreover, two patients failed initial
endovascular reintervention and required hybrid or open
repair, including zone 0 hybrid arch debranching and
open descending thoracic aneurysm repair. These special-
ized repairs highlight the importance of life-long aortic
surveillance by an experienced aortic referral center
following endovascular treatment of acute type B dissection
in order to identify and treat complications of the under-
lying disease process and treatment, as well as new aortic
pathologies, as they arise.
The reintervention rates in the present study appear
higher than prior reports, likely due to the longer durationof follow-up.13 It is also important to note that, despite the
increased reintervention rate over open repair, the majority
of these reinterventions are successfully managed with
endovascular techniques. Additionally, Kaplan-Meier anal-
ysis demonstrated that reintervention does not worsen
long-term survival.
There are several limitations to the current study. It
represents a retrospective analysis of prospectively collected
data. Second, despite representing the largest cohort with
the longest follow-up to date, the number of patients is
small given the single institution nature of the study, and
a larger trial with a multicenter registry is recommended
to substantiate the ﬁndings and establish long-term
($10 years) durability and safety of stent grafting for acute
complicated type B aortic dissection. Finally, in the current
era, the purest indications for TEVAR in the setting of
acute type B aortic dissection are malperfusion and
rupture,41 and these two indications were the only inclu-
sion criteria for enrollment in the recently completed
Gore C-TAG and Medtronic Valiant clinical trials exam-
ining the role of TEVAR in acute, complicated type B
dissection.25,26 Although the majority of patients in the
current study (66%) were treated for malperfusion and/
or contained or free rupture, an additional 34% were
treated for unrelenting chest and/or back pain. This latter
indication is a “softer call” for TEVAR in acute type B
aortic dissection, although data from IRAD has previously
demonstrated signiﬁcantly higher in-hospital mortality with
Fig 5. Comparison of actuarial (Kaplan-Meier) overall survival between patients who did (dashed line) or did not (solid
line) require reintervention. SE, Standard error.
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cohort with 36% in-hospital mortality for medically
managed patients with refractory pain, as this is an often
ominous sign of impending rupture.10 The authors of
this IRAD study concluded that TEVAR may be indicated
for refractory pain, as intervention was associated with
improved outcomes over medical management, and this
has been our institutional practice based on this data.
However, the inclusion of patients without rupture or mal-
perfusion in the current report may potentially contribute
to the improved outcomes observed.
CONCLUSIONS
In summary, TEVAR for acute complicated type B
aortic dissection reliably relieves malperfusion and effec-
tively mitigates impending and frank rupture with results
far superior to those previously reported for open repair.
It would appear that endovascular therapy represents a clear
advance in the management of this morbid condition.
Potential beneﬁts are mitigated by the need for reinterven-
tions, which appear higher than conventional open repair.
Fortunately, the majority of these reinterventions are
successfully managed with endovascular techniques and
do not confer a survival disadvantage. Additionally,
TEVAR for acute complicated type B aortic dissection
provides a durable long-term repair, as demonstrated bythis study with the largest cohort and the longest follow-
up to date. Drawing upon parallel results from other series,
TEVAR appears to have secured a ﬁrm position in the
armamentarium for the treatment of acute complicated
type B dissection.
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Submitted Feb 4, 2013; accepted Jul 10, 2013.DISCUSSIONDr Mark A. Farber (Chapel Hill, NC). The authors have
updated the details of their dissection cohort published just
a few years ago. It now includes 50 patients treated for acute
type B aortic dissection using TEVAR. Their technical success in
treating these patients is reported as 98%. It should be stressed,
however, that the reintervention rate at a mean follow-up of 34
months was signiﬁcant, with 26% of the patients requiring
secondary procedures at a mean interval of 4.5 months. They
have demonstrated excellent outcomes in this difﬁcult group of
patients and have added to the growing literature of support in
favor of TEVAR for acute aortic syndromes.
I have three questions for the authors:
1. It has been our practice since 2008 to routinely extend the
endograft treatment to within 5-8 cm of the celiac artery to
minimize the incidence of reintervention rates. In light to
your previous report, did you compare this new cohort of
patients to determine if there were differences in outcomes
or practice patterns over time that altered your results?
2. You have detailed the use of IVUS and its utility in performing
these procedures. It appears from the manuscript, however,
that you rely on angiography and TEE to determinecompleteness of the repair. Can you explain the role of
IVUS in determining unresolved dynamic malperfusion
compared to TEE and angiography?
3. Lastly, it has been our experience, as well as others, that
patients with DeBakey type IIIA dissections have better results
with less reinterventions than those with type IIIB dissections.
Did you speciﬁcally look at this subgroup in you analysis?
Dr Jennifer M. Hanna. So, to the ﬁrst question, our practice
has evolved in that we now have a much lower threshold to pave
the aorta down to the celiac axis in order to cover any and all
thoracic fenestrations that are either seen on angiography or
TEE in the OR. Ultimately, if we saw persistent ﬂow in the false
lumen, then we would not hesitate to cover that area.
As to the second question, this brings up a good point.
Although not mentioned in the talk, IVUS is actually used to
conﬁrm true lumen re-expansion and resolution of dynamic mal-
perfusion after thoracic endografting with or without distal stent
graft placement. It, therefore, plays a complimentary role to
angiography.
As to the last question, there were no type IIIA endoleaks in
our patient cohort.
